RJA
VNDA icon

Raymond James & Associates’s Vanda Pharmaceuticals VNDA Stock Holding History

Raymond James & Associates’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,000
Closed -$41.1K – 4091
2024
Q1 		$41.1K Hold
10,000
– – ﹤0.01% 3823
2023
Q4 		$42.2K Buy
+10,000
New +$40.3K ﹤0.01% 3722
2016
Q2 		– Sell
-19,051
Closed -$159K – 3097
2016
Q1 		$159K Buy
+19,051
New +$156K ﹤0.01% 2630

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's VNDA Position: Q2 2024 in Review

Raymond James & Associates sold out of Vanda Pharmaceuticals (VNDA) in Q2 2024, closing a stake of 10,000 shares — an estimated $41.1K sold.

Raymond James & Associates first reported a position in VNDA in Q1 2016 and held it in 3 quarters. The position peaked at $159K in Q1 2016. 148 funds tracked by Wall St. Rank hold VNDA as of Q2 2024.

  • Raymond James & Associates reported no remaining Vanda Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Raymond James & Associates sold 10,000 Vanda Pharmaceuticals shares in Q2 2024, an estimated $41.1K.
  • Raymond James & Associates first reported a position in Vanda Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • Raymond James & Associates's Vanda Pharmaceuticals position peaked at $159K in Q1 2016.
  • 148 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2024.

Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.